|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ަ����ѿ�� |
|
���� |
|
���� |
| ��������������� | |
|
��˼ƽ |
|
��һԪ |
| PubMed | |
|
Article by ZHANG Si-ping |
|
Article by ZHU Yi-yuan |
ަ����ѿ�ķ������Ƽ����ƽ�չ
��˼ƽ1, ��һԪ2
1. ����ʡ��ҽԺƤ����, �Ϸ�230001;
2. ����ҽ�ƴ�ѧ����ҽԺƤ����
ަ����ѿ�ķ�������Ŀǰ�Բ����,��������ަ����ѿ��Ƥ���ܰ�ϸ���鳲���ơ��ܰ�ϸ�������쳣�Լ������쳣���о�,Ϊ��ʾަ����ѿ�����Լ������ṩ��һЩ�µĹ۵㡣����ͳ�Ĺ⻯ѧ�Ʒ������ơ����ơ�����⻯ѧ�Ʒ���,άA���ࡢ�����ء�����2�ںϵ��ס��������12����Դ������¡��������ߵ��ڼ�������ަ����ѿ���нϺõ���Ч��
Advances in the Research of Pathogenesis and Treatment of Mycosis Fungoides
Department of Dermatology, Anhui Provincial Hospital, Hefei 230001, China
Department of Dermatology, Anhui Provincial Hospital, Hefei 230001, China
The pathogenesis of mycosis fungoides is unknown at present. Recently, studies on the homing mechanism of lymphocytes to the skin as well as on the abnormality of lymphocytes apoptosis and genes have provided new insights into the pathogenesis and therapy of mycosis fungoides. In addition to traditional photochemotherapy, radiotherapy, chemotherapy, and extracorporeal photochemotherapy, immunomodulators, such as tretinoins, interferons, interleukin-2 fusion protein, recombinant interleukin 12 and humanized monoclonal antibody may have a good therapeutic effect on the treatment of early stage mycosis fungoides.
[2] Ferenczi K,Fuhlbrigge RC,Pinkus J,et al.Increased CCR4 expression in cutaneous T cell lymphoma.J Invest Dermatol,2002,119:1405-1410.
[3] Zoi-Toli O,Vermeer MH,De Vries E,et al.Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL):association between lack of Fas expression and aggressive types of CTCL.Br J Dermatol,2000,143:313-319.
[4] Rook AH,Vowels BR,Jaworsky C,et al.The immunopathogenesis of cutaneous T-cell lymphoma.Abnormal cytokine production by Sezary T cells.Arch Dermatol,1993,129:486-489.
[5] Mao X,Orchard G,Lillington DM,et al.Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.Blood,2003,101:1513-1519.
[6] Scarisbrick JJ,Woolford AJ,Russell-Jones R,et al.Allelotyping in mycosis fungoides and Sezary syndrome:common regions of allelic loss identified on 9p,10q,and 17p.J Invest Dermatol,117:663.
[7] Navas IC,Algara P,Mateo M,et al.pl6(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides.Lab Invest,2002,82:123-132.
[8] Garatti SA,Roscetti E,Trecca D,et al.bcl-1,bcl-2,p53,c-myc,and lyt-10 analysis in cutaneous lymphomas.Recent Results Cancer Res,1995,139:249-261.
[9] Herrmann JJ,Roenigk HH Jr,Hurria A,et al.Treatment of mycosis fungoides with photochemotherapy (PUVA):long-term follow-up.J Am Acad Dermatol,1995,33(2 Pt 1):234-242.
[10] Stern RS,Bolshakov S,Nataraj AJ,et al.p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients:evidence for heterogeneity and field cancerization.J Invest Dermatol 2002,119:522-526.
[11] Diederen PV,van Weelden H,Sanders C J,et al.Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides:a retrospective study.J Am Acad Dermatol,2003,48:2159.
[12] Jones GW,Rosenthal D,Wilson LD.Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome).Cancer,1999,85:1985-1995.
[13] Von Hoff DD,Dahlberg S,Hartstock RJ,et al.Activity of fludarabine monophosphate in patients with advanced mycosis fungoides:a Southwest Oncology Group study.J Natl Cancer Inst,1990,82:1353-1355.
[14] Dolan ME,McRae BL,Ferries-Rowe E,et al.O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma:implications for treatment with alkylating agents.Clin Cancer Res,1999,5:2059-2064.
[15] Wollina U,Graefe T,Karte K.Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.J Am Acad Dermatol,2000,42(1 Pt 1):40-46.
[16] Zhang C,Hazarika P,Ni X,et al.Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells:relevance to mechanism of therapeutic action.Clin Cancer Res,2002,8:1234-1240.
[17] Talpur R,Ward S,Apisarnthanarax N,et al.Optimizing bexarotene therapy for cutaneous T-cell lymphoma.J Am Acad Dermatol,2002,47:672-684.
[18] Breneman D,Duvic M,Kuzel T,et al.Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.Arch Dermatol,2002,138:325-332.
[19] Chiarion-Sileni V,Bononi A,Fornasa CV,et al.Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.Cancer,2002,95:569-575.
[20] Yoo EK,Rook AH,Elenitsas R,et al.Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma:relevance to mechanism of therapeutic action.J Invest Dermatol,1996,107:235-242.
[21] Gottlieb SL,Wolfe JT,Fox FE,et al.Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa:a 10-year experience at a single institution.J Am Acad Dermatol,1996,35:946-957.
[22] Foss FM.DAB(389)IL-2 (ONTAK):a novel fusion toxin therapy for lymphoma.Clin Lymphoma,2000,1:110-116.
[23] Rook AH,Wood GS,Yoo EK,et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood,1999,94:902-908.
[24] Zaki MH,Wysocka M,Everetts SE,et al.Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2:basis for therapy of cutaneous T cell lymphoma.J Invest Dermatol,2002,118:366-371.
[25] Pawson R,Dyer M J,Barge R,et al.Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.J Clin Oncol,1997,15:2667-2672.